@article{ce8c761948154ff3bdb68827ffd72122,
title = "Selective depletion of radiolabeled HER2-specific antibody for contrast improvement during PET",
abstract = "The prolonged in vivo persistence of antibodies results in high background and poor contrast during their use as molecular imaging agents for positron emission tomography (PET). We have recently described a class of engineered Fc fusion proteins that selectively deplete antigen-specific antibodies without affecting the levels of antibodies of other specificities. Here, we demonstrate that these Fc fusions (called Seldegs, for selective degradation) can be used to clear circulating, radiolabeled HER2-specific antibody during diagnostic imaging of HER2-positive tumors in mice. The analyses show that Seldegs have considerable promise for the reduction of whole-body exposure to radiolabel and improvement of contrast during PET.",
keywords = "Engineered Fc fusions, HER2, PET",
author = "Priyanka Khare and Wei Sun and Sreevidhya Ramakrishnan and Guiyang Hao and Lo, {Su Tang} and Kien Nham and Xiankai Sun and Ober, {Raimund J.} and Ward, {E. Sally} and Rafal Swiercz",
note = "Funding Information: This work was supported in part by grants from the Cancer Prevention and Research Institute of Texas [RP160051] and Cancer Research UK [A24722]. We thank Drs. John Minna and Kenneth Huffman (UT Southwestern Medical Center) for providing the HCC1954 breast cancer cell line. We are grateful to Drs. Siva Devanaboyina and Dilip Challa for their assistance. We also thank Dr. Richard Stopforth for providing recombinant mouse FcRn for use in SPR experiments. Funding Information: This work was supported in part by the Cancer Prevention and Research Institute of Texas (RP160051). E.S.W. and R.J.O. are co-inventors on a pending patent describing Seldegs. E.S.W. and R.J.O. may receive royalties from patents owned by the UK Medical Research Council, UT Southwestern Medical Center and Texas A&M University. E.S.W. and R.J.O. have a financial interest in argenx, Astero Biopharma LLC, Astero Erado Inc. and Astero Technologies LLC. P.K., W.S., S.R., R.S., G.H., S-T.L., K.N. and X.S. do not have any disclosures. Publisher Copyright: {\textcopyright} 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.",
year = "2021",
doi = "10.1080/19420862.2021.1976705",
language = "English (US)",
volume = "13",
journal = "mAbs",
issn = "1942-0870",
publisher = "Landes Bioscience",
number = "1",
}